Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dyslipidemia
Interventions: JTT-302, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Healthy
Interventions: Single-Dose IV Oritavancin Diphosphate and Warfarin, Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Polycystic Kidney Disease, Autosomal Dominant
Interventions: RGLS4326; Drug
Lead sponsor: Regulus Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: La Mesa, California • Los Angeles, California • New Haven, Connecticut + 8 more

Conditions: Liver Transplant
Interventions: Immunosuppression Reduction; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 13 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Obstructive Sleep Apnea of Adult
Interventions: Verily Sleep Apnea (VSA) Program/App; Device
Lead sponsor: Verily Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: South San Francisco, California

Conditions: Healthy
Interventions: Brain Computer Interface Switch; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Smoking Cessation, Alcohol Drinking
Interventions: Chantix, Behavioral Counseling Sessions, NicodermCQ, Placebo; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Safety Issues
Interventions: Nicotine Bitartrate Lozenge 4mg, Nicotine Polacrilex 4Mg Lozenge; Drug
Lead sponsor: Niconovum USA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets (20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Schizophrenia, Suicide
Interventions: Enhanced Treatment as Usual, Coping Long-term with Active Suicide Program for Schizophrenia; Behavioral
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cystic Fibrosis
Interventions: hypertonic saline (7%), isotonic saline; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
U.S. locations: 8
States / cities: Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more

Conditions: Melanoma
Interventions: Melaxin (autologous dendritoma vaccine) and BCG; Biological
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Cannabis Use Disorder, Cannabis Dependence, Continuous
Interventions: 11C-OMAR, Cannabis; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometrial Bleeding, Periodontal Disease
Interventions: doxycycline; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Heavy Drinking, Driving Under the Influence, Riding With Driver Under the Influence
Interventions: Computer-facilitated Screening and Brief Intervention; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 17 Years
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Itasca, Illinois • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: STAKEL; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Odronextamab multiple dose levels; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Tampa, Florida + 4 more

Conditions: Melanoma
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Louisville, Kentucky • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: bevacizumab, cytarabine, mitoxantrone hydrochloride; Biological · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland

Conditions: Anesthesia
Interventions: Needle-Free Jet Injection of 1 % lidocaine, traditional needle infiltration of 1% lidocaine; Device · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Day to 3 Months
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

Baseline Sleep Apnea Study #2

Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations

Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders

Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Brain Imaging of Cannabinoid Receptors

Norplant and Irregular Bleeding/Spotting

Adolescent Substance Use Prevention Intervention Research Study in Pediatric Primary Care

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Needle-Free Lidocaine Injection vs Traditional Local Anesthesia in Infant Lumbar Puncture